secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001711279-23-000014
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech appoints Catherine Mazzacco to Board of Directors
-----------------------------------------------------------------

- Board expanded from 8 to 9 directors; Catherine Mazzacco appointed as independent Class I director effective March 6, 2023.
- Mazzacco will serve on the Nominating and Corporate Governance committee and stand for election at 2024 annual meeting.
- She previously served as CEO & President of LEO Pharma and SVP at GE HealthCare, with 25+ years at Abbott Laboratories.
- No material transactions or arrangements between Mazzacco and the company; standard director compensation applies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000014/0001711279-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000014/krys-20230306.htm
  HTML page:      https://secwatch.observer/filing/0001711279-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer